FREMONT, Calif. and WALTHAM,
Mass., May 25, 2021
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a
biopharmaceutical company focused on developing innovative
first-in-class medicines to improve treatment for people with
kidney and cardiorenal diseases, today announced that Mike Raab, president and chief executive officer
of Ardelyx, will participate in a fireside chat at the Jefferies
Virtual Healthcare Conference on Tuesday,
June 1, 2021 at 3:30 p.m. ET.
To access the live webcast of Ardelyx's presentation please
visit the Events & Presentations page within the Investor
section of the Ardelyx website at ir.ardelyx.com. A replay of the
webcast will be available on the Ardelyx website for 60 days
following the conference.
About Ardelyx, Inc.
Ardelyx is focused on discovering,
developing and commercializing innovative first-in-class medicines
to enhance the lives of patients with kidney and cardiorenal
diseases. Ardelyx is advancing tenapanor, a novel product candidate
to control serum phosphorus in adult patients with CKD on dialysis,
for which the company's NDA is currently under review by the FDA.
Ardelyx is also advancing RDX013, a potassium secretagogue, for the
potential treatment of elevated serum potassium, or hyperkalemia, a
problem among certain patients with kidney and/or heart disease and
has an early-stage program in metabolic acidosis, a serious
electrolyte disorder in patients with CKD. In addition, Ardelyx
received FDA approval of IBSRELA® (tenapanor) on
September 12, 2020. Ardelyx has
established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and
commercialization of tenapanor in their respective territories.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-jefferies-2021-virtual-healthcare-conference-301298423.html
SOURCE Ardelyx